Sex, Age, Race Affected SCC Risk Among Melanoma Patients

“Approximately 12% of patients with melanoma developed subsequent squamous cell carcinoma, and the occurrence was more common among men, whites, older patients and those with a history of nonmelanoma skin cancer, according to recent study results.

“Researchers studied 6,378 Kaiser Permanente Northern California (KPNC) members (mean age, 60.9 years; 56.6% men) who received a melanoma diagnosis between 2000 and 2005. The patients were followed through 2009, with 1,462 meeting criteria for squamous cell carcinoma (SCC) pathology review. There were 766 patients with defined SCC (69.7% men).”


Young Skin Cancer Survivors at Risk of Other Cancers Later

“Young people who have been diagnosed with non-melanoma skin cancer related to sun exposure, under the age of 25, face a higher risk of developing melanoma and other cancers later in life, a study has shown. The researchers found that those who had NMSC under 25 years of age were 53 times more likely to get bone cancer, 26 times more likely to get blood cancers, 20 times more likely to get brain cancer, and 14 times more likely to get any cancer excluding those of the skin.”


Plexxikon updates Zelboraf Phase 1 data on BRAF V600E mutation-positive melanoma

Plexxikon today announced that updated Phase 1 clinical data of Zelboraf (vemurafenib) were presented at the Society for Melanoma Research (SMR) 2012 Congress, held November 8-11 in Los Angeles, CA.


Combined BRAF and MEK Inhibition Improves Outcome in Metastatic Melanoma

The combination of dabrafenib and trametinib is safe and effective in BRAF-mutant melanoma.


PLOS ONE: The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis

PLOS ONE: an inclusive, peer-reviewed, open-access resource from the PUBLIC LIBRARY OF SCIENCE. Reports of well-performed scientific studies from all disciplines freely available to the whole world.


How necessary is a sentinel node biopsy for melanoma?

A new report weighs the pros and cons of a sentinel node biopsy for melanoma patients.


National Cancer Institute Report shows cancer death rates dropping for most but not all cancers

The Annual Report on the status of cancer shows a decline in cancer deaths from major cancers including lung, colorectal, prostate, and breast, but some cancer deaths continue to increase specifically for men with melanoma as well as for those with liver, uterine, and pancreatic cancers.


Sorafenib does not improve survival in metastatic melanoma Phase III Trial Shows

Sorafenib plus chemotherapy did not improve the overall survival of metastatic melanoma patients not previously treated with chemotherapy. The trial results are published in the Journal of Clinical Oncology.


Wound Complications after Inguinal Lymph Node Lower Than Previously Reported Than in Previous Single Institution Trials

Of 281 cutaneous melanoma patients undergoing inguinal lymph node (ILND) dissection, 14% had wound complications, a rate much lower than those reported in previous single institution studies. In a multivariable model, obesity, and diabetes were significantly associated with wound complications. There was no difference in the rate of reoperation in patients with and without wound complications. The study concludes that the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) appears to underreport the actual incidence of wound complications after ILND.